Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

UroGen Pharma (URGN) Asset Writedowns and Impairment (2022)

UroGen Pharma's Asset Writedowns and Impairment history spans 1 years, with the latest figure at $255000.0 for Q4 2022.

For Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to $255000.0; the TTM value through Dec 2023 reached $605000.0, changed 0.0%, while the annual FY2022 figure was $870000.0, N/A changed from the prior year.
Asset Writedowns and Impairment reached $255000.0 in Q4 2022 per URGN's latest filing, down from $350000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $350000.0 in Q3 2022 to a low of $255000.0 in Q4 2022.